| Expression pattern: |
UP |
| Associated gene: |
IGF2BP1, CXCL5 mRNA |
| Associated microRNA: |
- |
| Biological function: |
Promotes Ang II-induced HA-VSMCs proliferation, migration and phenotypic switch; contributes to TAD progression. |
| Molecular mechanism: |
circNRIP1 recruits/binds IGF2BP1 and increases CXCL5 mRNA stability, thereby promoting CXCL5 expression. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); mRNA stability (promotes); other pathway/process (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; RT-qPCR; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Actinomycin D / DRB Stability Assay; Transfection; EdU Staining; Transwell Assay; Wound Healing Assay; Western Blot; Bioinformatics Analysis |
| Clinical significance: |
High circNRIP1 expression was associated with hypertension and D-dimer of TAD patients; targeting circNRIP1/IGF2BP1/CXCL5 axis may be an effective measure for TAD treatment. |
| Description: |
circNRIP1 is up-regulated in TAD patient aortic specimens and Ang II-induced HA-VSMCs. It promotes HA-VSMC proliferation, migration and phenotypic switch by binding/recruiting the RBP IGF2BP1 to enhance CXCL5 mRNA stability, suggesting the circNRIP1/IGF2BP1/CXCL5 axis as a potential therapeutic target for TAD. |
| Confidence score: |
0.7968 |